Talquetamab vs Real-World Physician's Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent

被引:0
|
作者
Mateos Manteca, Maria-Victoria [1 ]
Jakubowiak, Andrzej [2 ]
Einsele, Hermann [3 ]
Schinke, Carolina [4 ]
Besemer, Britta [5 ]
Anguille, Sebastien [6 ]
Manier, Salomon [7 ]
Rasche, Leo [8 ]
Goldschmidt, Hartmut [9 ]
van de Donk, Niels [10 ,11 ]
Perrot, Aurore [12 ]
Teipel, Raphael [13 ]
Karlin, Lionel [14 ]
Scheid, Christof [15 ]
San-Miguel, Jesus [16 ]
Pawlyn, Charlotte [17 ,18 ]
Martinez-Lopez, Joaquin [19 ]
Cavo, Michele [20 ]
Diels, Joris [21 ]
Renaud, Thomas [22 ]
Orel, Oleksiy [23 ]
Cabrieto, Jedelyn [21 ]
Perualila, Nolen [21 ]
Weisel, Katja [24 ]
Moreau, Philippe [25 ]
机构
[1] Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, CIBERONC, Salamanca, Spain
[2] Univ Chicago, Chicago, IL USA
[3] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[4] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA
[5] Univ Tubingen, Tubingen, Germany
[6] Univ Antwerp, Antwerp Univ Hosp, Ctr Cell Therapy & Regenerat Med, Vaccine & Infect Dis Inst, Antwerp, Belgium
[7] Univ Lille, CHU Lille, Lille, France
[8] Univ Hosp Wurzburg, Wurzburg, Germany
[9] Univ Hosp Heidelberg, GMMG Study Grp, Dept Internal Med 5, Heidelberg, Germany
[10] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands
[11] Canc Ctr Amsterdam, Amsterdam, Netherlands
[12] Univ Toulouse, Serv Hematol, Toulouse, France
[13] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany
[14] Ctr Hosp Lyon Sud, Lyon, France
[15] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[16] Clin Univ Navarra, Navarra, Spain
[17] Inst Canc Res, London, England
[18] Royal Marsden NHS Fdn Trust, London, England
[19] Univ Complutense Madrid, CNIO Clin Res Unit H12O, CIBERONC, Dept Hematol,Hosp 12 Octubre, Madrid, Spain
[20] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
[21] Janssen Pharmaceut NV, Beerse, Belgium
[22] Janssen Res & Dev, Raritan, NJ USA
[23] Janssen Cilag GmbH, Neuss, Germany
[24] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[25] Univ Hosp Hotel Dieu, Hematol Dept, Beirut, Lebanon
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P-050
引用
收藏
页码:S69 / S70
页数:2
相关论文
共 50 条
  • [41] Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
    Sean Bujarski
    Kyle Udd
    Camilia Soof
    Haiming Chen
    Tanya M. Spektor
    Tahmineh Safaie
    Mingjie Li
    Joshua Stern
    Cathy Wang
    Ning Xu
    Marsiye Emamy-Sadr
    Regina Swift
    Ashkon Rahbari
    Saurabh Patil
    Eric Souther
    Bernard Regidor
    Christine Sutanto
    James R. Berenson
    Targeted Oncology, 2021, 16 : 503 - 515
  • [42] Incidence of acute kidney injury in patients with relapsed and refractory multiple myeloma treated with teclistamab vs chimeric antigen receptor T-cell therapy
    Charkviani, Mariam
    Vaughan, Lisa E.
    Sandahl, Tyler B.
    Lin, Yi
    Leung, Nelson
    Herrmann, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] DURABLE RESPONSES FOLLOWING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/ REFRACTORY LARGE B-CELL LYMPHOMA AFTER MULTIPLE LINES OF TREATMENT: THE HELLENIC REAL-WORLD EXPERIENCE
    Bampali, Vasiliki
    Dolgyras, Panagiotis
    Matheakakis, Angelos
    Alexandropoulos, Alexandros
    Tsonis, Ioannis
    Gavriilaki, Eleni
    Tzannou, Ifigeneia
    Batsis, Ioannis
    Tzenou, Tatiana
    Mallouri, Despina
    Bouzani, Maria
    Vardi, Anna
    Anagnostopoulos, Achilles
    Gigantes, Stavros
    Sotiropoulos, Damianos
    Karakasis, Dimitrios
    Baltadakis, Ioannis
    Sakellari, Ioanna
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 211 - 211
  • [44] Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
    Charanpreet Singh
    Aditya Jandial
    Arihant Jain
    Deepesh Lad
    Alka Khadwal
    Rajender Basher
    Amanjit Bal
    Pankaj Malhotra
    Gaurav Prakash
    Indian Journal of Hematology and Blood Transfusion, 2024, 40 : 231 - 236
  • [45] Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
    Singh, Charanpreet
    Jandial, Aditya
    Jain, Arihant
    Lad, Deepesh
    Khadwal, Alka
    Basher, Rajender
    Bal, Amanjit
    Malhotra, Pankaj
    Prakash, Gaurav
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (02) : 231 - 236
  • [46] Real-World Evaluation of Outcomes in Relapsed/Refractory Multiple Myeloma Patients That Are Triple-Class Exposed after Receiving 2 or More Prior Lines of Therapy
    Radwanski, Katherine
    Yu, Junhua
    Pierce, Kody
    Talati, Chetasi
    Stricker, Steve
    Jiao, Shiyin
    Bueno, Orlando
    BLOOD, 2023, 142
  • [47] Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma
    Zhao, Wan-Hong
    Liu, Jie
    Wang, Bai-Yan
    Chen, Yin-Xia
    Cao, Xing-Mei
    Yang, Yun
    Zhang, Yi-Lin
    Wang, Fang-Xia
    Zhang, Peng-Yu
    Lei, Bo
    Gu, Liu-Fang
    Wang, Jian-Li
    Yang, Nan
    Zhang, Ru
    Zhang, Hui
    Shen, Ying
    Bai, Ju
    Xu, Yan
    Wang, Xu-Geng
    Zhang, Rui-Li
    Wei, Li-Li
    Li, Zong-Fang
    Li, Zhen-Zhen
    Geng, Yan
    He, Qian
    Zhuang, Qiu-Chuan
    Fan, Frank Xiao-Hu
    He, Ai-Li
    Zhang, Wang-Gang
    BLOOD, 2018, 132
  • [48] A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Dongjian
    Zhu, Yu
    Chen, Zhi
    Jiang, Songfu
    He, Haiyan
    Qiang, Wanting
    Xiang, Fang
    Sun, Xuedong
    Du, Juan
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3747 - 3756
  • [49] Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies
    Raab, M. S.
    Hanel, M.
    Nooka, A. K.
    Lesokhin, A. M.
    Mohty, M.
    Niesvizky, R.
    Maisel, C.
    Arnulf, B.
    Larson, S. M.
    Varshavsky-Yanovsky, A. N.
    Leleu, X.
    Karlin, L.
    Vesole, D. H.
    Bahlis, N. J.
    de larrea, Fernandez C.
    Raje, N.
    Leip, E.
    Conte, U.
    Elmeliegy, M.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 232 - 232
  • [50] Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Bonifacio, Massimiliano
    Papayannidis, Cristina
    Lussana, Federico
    Fracchiolla, Nicola
    Annunziata, Mario
    Sica, Simona
    Delia, Mario
    Foa, Robin
    Pizzolo, Giovanni
    Chiaretti, Sabina
    FRONTIERS IN ONCOLOGY, 2022, 11